Health and pharmaceutical industry Health and pharmaceutical industry

Health is widely recognized as a state of wellbeing that allows physical and mental functions to be exercised normally, which is why there are different governments health policies that facilitate access and effective attention in the health system. The problem arises when there is a debate about whether health is a right or a business and if its coverage should be public or private since financial sustainability and broad coverage are the pillars of an efficient health system.

All health services and their supplements such as medical appointments, laboratory exams, health teams, medicines, require financing so health systems go to taxes and social security for employees to achieve sustainability and thus attend to the population. The problem is that in many cases money is not enough and the quality of health ends up being precarious, exhorting society look for different options such as private health services companies that are generally expensive. In the United States, health is so expensive that in 2010 there were around 50 million people without health insurance, then it is understandable that governments subsidize the most vulnerable population, so that they can be treated with a relative good quality.

Medicines are part of a market with high demand and very profitable. Every day there are new patients that require drugs to prevent, heal or treat a disease, hence the pharmaceutical industry generates about 1 billion of income worldwide. Although generic drugs and high life expectancy have an impact on the profitability of the sector, each year future patients are born and new conditions appear that stimulate the supply and demand stability in the sector. On the other hand, there are diseases that require perpetual treatment such as hypertension or diabetes, guaranteeing large volumes of sales and permanent income to the pharmaceutical industry, which until now has avoided technological advances in health.